Article

Warburg Pincus completes acquisition of Bausch & Lomb

New York-Affiliates of private equity firm Warburg Pincus have completed the acquisition of Bausch & Lomb (B&L) for approximately $4.5 billion, including about $830 million of debt.

New York

-Affiliates of private equity firm Warburg Pincus have completed the acquisition of Bausch & Lomb (B&L) for approximately $4.5 billion, including about $830 million of debt.  

“With a strong and supportive partner in Warburg Pincus, we are well-positioned to create new opportunities for [B&L] and advance our leadership in the eye health industry,” said Ronald L. Zarrella, chairman and chief executive officer of B&L, Rochester, NY.
 
Elizabeth H. Weatherman, a Warburg Pincus managing director, said, “We look forward to helping the company build upon its rich heritage and premier brand in ophthalmology.”

B&L stock has been delisted on the New York Stock Exchange. Under the terms of the acquisition agreement, B&L shareholders are entitled to receive $65 in cash for each share of B&L common stock that they hold.

 

Related Videos
(Image credit: Ophthalmology Times) NeuroOp Guru: The role of muscle biopsy in heteroplasmy detection
(Image credit: Ophthalmology Times) AGS 2025: Achieving success as an academic ophthalmologist with Thomas V. Johnson III, MD, PhD
(Image credit: Ophthalmology Times) AGS 2025: Constance Okeke, MD, highlights 1-year Streamline canaloplasty outcomes
(Image credit: Ophthalmology Times) AGS 2025: Telemedicine and genetics for resource-efficient care with Louis R. Pasquale, MD
© 2025 MJH Life Sciences

All rights reserved.